Question 1

What is Insulet's P/B ratio?

Accepted Answer

Insulet (PODD) P/B ratio is 8.6× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Insulet?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Insulet specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

Is Insulet's P/B ratio high or low?

Accepted Answer

Insulet's P/B ratio of 8.6× is below its own 5-year average of 25.8× and above the sector median of 3.2×. That places the current reading at the 4th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Insulet's historical P/B ratio range?

Accepted Answer

In the available daily series, Insulet (PODD) P/B ratio has ranged from a low of 1.7× in 2007 to a high of 1038.1× in 2009. The 5-year average is 25.8× and the 5-year median is 19.5×.

Question 7

What was Insulet's P/B ratio in 2025?

Accepted Answer

Insulet (PODD) P/B ratio at the end of 2025 was 13.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Insulet's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$20B	$1.52B	13.2×	-1.9×	Dec 31, 2025
2024	$18.3B	$1.21B	15.1×	-5.6×	Dec 31, 2024
2023	$15.2B	$733M	20.7×	-22.2×	Dec 31, 2023
2022	$20.5B	$476M	42.9×	+9.9×	Dec 31, 2022
2021	$18.4B	$556M	33.0×	+5.1×	Dec 31, 2021
2020	$16.9B	$604M	27.9×	-112.8×	Dec 31, 2020
2019	$10.7B	$75.9M	140.7×	+118.6×	Dec 31, 2019
2018	$4.69B	$212M	22.1×	-2.8×	Dec 31, 2018
2017	$3.95B	$159M	24.9×	-8.4×	Dec 31, 2017
2016	$2.1B	$63.2M	33.2×	-30.0×	Dec 31, 2016
2015	$2.15B	$34.1M	63.2×	+32.4×	Dec 31, 2015
2014	$2.59B	$83.8M	30.9×	+14.6×	Dec 31, 2014
2013	$2.03B	$125M	16.3×	-6.9×	Dec 31, 2013
2012	$1.02B	$44.2M	23.2×	+10.7×	Dec 31, 2012
2011	$893M	$71.4M	12.5×	+1.8×	Dec 31, 2011
2010	$707M	$66.2M	10.7×	+0.4×	Dec 31, 2010
2009	$541M	$52.9M	10.2×	-39.9×	Dec 31, 2009
2008	$214M	$4.27M	50.1×	+43.2×	Dec 31, 2008
2007	$639M	$92.3M	6.9×	—	Dec 31, 2007
2006	$14.6M	-$102M	—	—	Dec 31, 2006
2005	$12.7M	-$66.1M	—	—	Dec 31, 2005


Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for Insulet (PODD) 2007-2026

P/B Ratio daily chart for Insulet (PODD)

Historical P/B Ratio for Insulet (PODD) from 2005 to 2025

About P/B Ratio at Insulet (PODD)

Insulet P/B Ratio by Year

Insulet P/B Ratio 2025: 13.2×

Insulet P/B Ratio 2024: 15.1×

Insulet P/B Ratio 2023: 20.7×

Insulet P/B Ratio 2022: 42.9×

Insulet P/B Ratio 2021: 33.0×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Insulet (PODD) Key Financials